title: Induction therapy with basiliximab and full HLA mismatch.
abstract: BACKGROUND
  Induction therapy reduces rejection episodes among patients at high immunologic risk. Antithymocyte globulins appear to be superior to basiliximab in this population, despite the greater potential risk of infection and neoplasia. The aim of this study was to evaluate graft function and acute rejection episodes in 6 HLA-mismatched patients who underwent induction with basiliximab but had no other immunologic risk factors.
  
  
  METHODS
  We analyzed retrospectively patients who were transplanted using basiliximab for induction therapy during a 4 year period, comparing patients with full HLA mismatches with those who had 5 or fewer mismatches. None of the patients had other immunological risk factors for rejection.
  
  
  RESULTS
  We observed no significant differences between the groups concerning demographic features, cold ischemia times, and panel reactive antibodies. Graft function at 12 and 24 months was not different between both groups. Acute rejection episodes were also not different between groups.
  
  
  CONCLUSIONS
  In this population of full HLA mismatches and no other immunological risk factors, induction immunosuppression therapy with basiliximab was safe in terms of graft function and acute rejection episodes.
authors.affiliation: cristinaouterelo@gmail.com
authors.forename: C
authors.initials: C
authors.lastname: Outerelo
authors.forename: R
authors.initials: R
authors.lastname: Gouveia
authors.forename: A
authors.initials: A
authors.lastname: Mateus
authors.forename: P
authors.initials: P
authors.lastname: Cruz
authors.forename: C
authors.initials: C
authors.lastname: Oliveira
authors.forename: A
authors.initials: A
authors.lastname: Ramos
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000077552:Basiliximab; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006680:HLA Antigens / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D008297:Male; D011300:Preoperative Care; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D012189:Retrospective Studies
chemical_list: D000911:Antibodies, Monoclonal; D006680:HLA Antigens; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab